A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy

Status Recruiting

Clinical Trial Summary

The main purpose of this study is to compare the change in pain intensity during treatment with a CGRP monoclonal antibody (eptinezumab) compared with placebo treatment in patients with painful diabetic polyneuropathy (DPN).

Clinical Trial Description

In neuropathy (nerve inflammation), which is seen in diabetes and other types of damage to the nerves, pain often occurs that can be difficult to treat. Some drugs have some effect on these pains, but unfortunately the treatment is not equally effective for all patients. It is not known why some patients achieve good pain relief with a given treatment. CGRP monoclonal antibody (eptinezumab) was originally developed as a drug for migraine and works by blocking molecules called CGRP that we, based on previous studies, play a major role in pain perception. Our previous studies have shown that patients with painful diabetic neuropathy (DPN) have increased incidence of the CGRP molecules in the skin precisely where patients experience pain compared to patients with painless DPN and healthy people without neuropathy. Eptinezumab is a Food and Drug Administration (FDA) approved drug for migraines, but it is not an approved drug for the treatment of DPN. The purpose of the trial is to investigate whether the treatment has an effect on the pain in the feet experienced by some patients with diabetes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05937152
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Recruiting
Phase	Phase 2
Start date	June 2024
Completion date	November 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06040567` - Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
Completed	`NCT02423434` - Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes
Completed	`NCT05542901` - Comparison of Joint Position Sense in Diabetic and Traumatic Transtibial Amputees	N/A
Withdrawn	`NCT01536236` - Spinal Cord Stimulation for Diabetic Polyneuropathy	N/A
Active, not recruiting	`NCT01175928` - Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral Neuropathy	Phase 1/Phase 2
Completed	`NCT00993070` - Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy	Phase 2/Phase 3
Completed	`NCT00539175` - Treatment of Painful Diabetic Neuropathy With Photon Stimulation	N/A
Completed	`NCT00278980` - Effect of C-Peptide on Diabetic Peripheral Neuropathy	Phase 2
Completed	`NCT04593992` - HTEMS Treatment of Diabetic Polyneuropathy	N/A
Completed	`NCT01465620` - Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study	Phase 3
Completed	`NCT01079325` - Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy	Phase 2
Completed	`NCT00406458` - Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy	Phase 2
Recruiting	`NCT06072573` - Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy	Phase 3
Recruiting	`NCT06071975` - Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy	Phase 3
Recruiting	`NCT05521737` - Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy	N/A
Completed	`NCT01847937` - Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy	N/A
Completed	`NCT00476931` - Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy	Phase 2
Completed	`NCT00977483` - Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)	Phase 3
Completed	`NCT01006915` - Surgical Decompression for Diabetic Neuropathy in the Foot	N/A
Completed	`NCT00501202` - Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).	Phase 2